ANAPTYSBIO, INC
NASDAQ: ANAB. Canonical company identity and public leadership record.
US
- Alpha ID
- alpha:company:1c68c29e-e367-49ef-8047-af2ac5518cee
- SEC CIK
- 0001370053
- Record version
- vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 16, 2026
- Newest evidence
- May 3, 2026
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- Daniel FagaSince Apr 29, 2025
- Chair
- Not published
- Independent
- 8 / 99 directors published
- Published claims
- 273 distinct sources
- Evidence records
- 90 pinned
- Source conflicts
- 0None open
Built from 3 distinct sources and 9 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
CEO CHANGED
Daniel Faga executive of ANAPTYSBIO, INC, effective 2025-04-29.
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
Evidence| Role | Person | Since | Status | Claim |
|---|---|---|---|---|
| President and Chief Executive Officer and Director | Daniel Faga | Apr 2025 | current | Source reportedE3 |
| Chief Financial Officer | Dennis Mulroy | Apr 2025 | current | Source reportedE4 |
| Chief Legal Officer | Eric Loumeau, J.D. | Apr 2025 | current | Source reportedE6 |
| Chief Medical Officer | Paul Lizzul, M.D., Ph.D. | Apr 2025 | current | Source reportedE8 |
| Chief Legal Officer | Eric Loumeau | Not captured | unknown | Source reportedE5 |
| Chief Medical Officer | Paul Lizzul | Not captured | unknown | Source reportedE7 |
Board of directors
Evidence9 directors published. 8 of 9 with a published determination are independent.
| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| Daniel Faga | Not independent | 2021 | None published | Source reportedE2 |
| Dennis Fenton, Ph.D. | Independent | 2018 | None published | Source reportedE2 |
| Hollings Renton | Independent | 2015 | Nominating and Governance, chairNominating and Governance · Chair | Source reportedE2 |
| J. Anthony Ware, M.D. | Independent | 2017 | None published | Source reportedE2 |
| John Orwin | Independent | 2023 | Nominating and Governance | Source reportedE2 |
| John Schmid | Independent | 2015 | Audit, chairAudit · Chair; CompensationCompensation | Source reportedE2 |
| Magda Marquet, PhD | Independent | 2021 | None published | Source reportedE2 |
| Oleg Nodelman | Independent | 2021 | Nominating and Governance | Source reportedE2 |
| Rita Jain, MD | Independent | 2023 | None published | Source reportedE2 |
Committees and risk ownership
Evidence| Committee | Chair | Members | Risks assigned |
|---|---|---|---|
| Audit | John Schmid | John Schmid | Not described in the published record |
| Audit · Chair; Compensation | Not published | John Schmid | Not described in the published record |
| Compensation | Not published | John Schmid | Not described in the published record |
| Nominating and Governance | Hollings Renton | Hollings Renton, John Orwin, Oleg Nodelman | Not described in the published record |
| Nominating and Governance · Chair | Not published | Hollings Renton | Not described in the published record |
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Financials and market context
EvidenceGovernance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- Daniel FagaPresident and Chief Executive Officer and Directorcompany:1c68c29e-e367-49ef-8047-af2ac5518cee:leadership_role:14
- Dennis MulroyChief Financial Officercompany:1c68c29e-e367-49ef-8047-af2ac5518cee:leadership_role:15
- Eric Loumeau, J.D.Chief Legal Officercompany:1c68c29e-e367-49ef-8047-af2ac5518cee:leadership_role:17
- Paul Lizzul, M.D., Ph.D.Chief Medical Officercompany:1c68c29e-e367-49ef-8047-af2ac5518cee:leadership_role:19
- Eric LoumeauChief Legal Officercompany:1c68c29e-e367-49ef-8047-af2ac5518cee:leadership_role:16
- Paul LizzulChief Medical Officercompany:1c68c29e-e367-49ef-8047-af2ac5518cee:leadership_role:18
- Daniel FagaDirectorcompany:1c68c29e-e367-49ef-8047-af2ac5518cee:leadership_role:5
- Dennis Fenton, Ph.D.Directorcompany:1c68c29e-e367-49ef-8047-af2ac5518cee:leadership_role:6
- Hollings RentonDirectorcompany:1c68c29e-e367-49ef-8047-af2ac5518cee:leadership_role:7
- J. Anthony Ware, M.D.Directorcompany:1c68c29e-e367-49ef-8047-af2ac5518cee:leadership_role:8
- John OrwinDirectorcompany:1c68c29e-e367-49ef-8047-af2ac5518cee:leadership_role:9
- John SchmidDirectorcompany:1c68c29e-e367-49ef-8047-af2ac5518cee:leadership_role:10
- Magda Marquet, PhDDirectorcompany:1c68c29e-e367-49ef-8047-af2ac5518cee:leadership_role:11
- Oleg NodelmanDirectorcompany:1c68c29e-e367-49ef-8047-af2ac5518cee:leadership_role:12
- Rita Jain, MDDirectorcompany:1c68c29e-e367-49ef-8047-af2ac5518cee:leadership_role:13
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 9 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 16, 2026. Cited by 4 Claims.
- E2sec proxy. Published Apr 29, 2025. Retrieved Apr 24, 2026. Cited by 9 Claims.
- E3sec filing. Published Apr 29, 2025. Retrieved May 14, 2026. Cited by 1 Claim.
- E4sec filing. Published Apr 29, 2025. Retrieved May 14, 2026. Cited by 1 Claim.
- E5ANAB executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E6sec filing. Published Apr 29, 2025. Retrieved May 14, 2026. Cited by 1 Claim.
- E7ANAB executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E8sec filing. Published Apr 29, 2025. Retrieved May 14, 2026. Cited by 1 Claim.
- E9board_seats. board seats. Cited by 8 Claims.
What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 16, 2026- Daniel Faga executive of ANAPTYSBIO, INC, effective 2025-04-29.
- Dennis Mulroy executive of ANAPTYSBIO, INC, effective 2025-04-29.
- Eric Loumeau, J.D. executive of ANAPTYSBIO, INC, effective 2025-04-29.
- Paul Lizzul, M.D., Ph.D. executive of ANAPTYSBIO, INC, effective 2025-04-29.
- John Orwin seat on ANAPTYSBIO, INC, effective 2023-01-01.
- Rita Jain, MD seat on ANAPTYSBIO, INC, effective 2023-01-01.
- John Orwin member of Nominating and Governance, effective 2023-01-01.
- Daniel Faga seat on ANAPTYSBIO, INC, effective 2021-01-01.
- Magda Marquet, PhD seat on ANAPTYSBIO, INC, effective 2021-01-01.
- Oleg Nodelman seat on ANAPTYSBIO, INC, effective 2021-01-01.
- Dennis Fenton, Ph.D. seat on ANAPTYSBIO, INC, effective 2018-01-01.
- J. Anthony Ware, M.D. seat on ANAPTYSBIO, INC, effective 2017-01-01.
- Hollings Renton seat on ANAPTYSBIO, INC, effective 2015-01-01.
- John Schmid seat on ANAPTYSBIO, INC, effective 2015-01-01.
- Audit · Chair; Compensation committee of ANAPTYSBIO, INC, effective 2015-01-01.
- John Schmid member of Audit · Chair; Compensation, effective 2015-01-01.
- Nominating and Governance · Chair committee of ANAPTYSBIO, INC, effective 2015-01-01.
- Hollings Renton member of Nominating and Governance · Chair, effective 2015-01-01.



